Overview

Investigator Initiated Phase 1 Study of TBI-1301

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Mie University
Collaborators:
Fiverings Co., Ltd.
Shionogi
Statcom Co. Ltd.
Takara Bio Inc.
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate